☆ 4.7 Meeting Abstract

PRELIMINARY RESULTS OF A PHASE 2 STUDY OF INTRATUMORAL ADMINISTRATION OF BO-112 WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA THAT HAVE PROGRESSIVE DISEASE ON ANTI-PD-1-BASED THERAPY

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER

Volume 9, Issue -, Pages A1011-A1012

Publisher

BMJ PUBLISHING GROUP

DOI: 10.1136/jitc-2021-SITC2021.961

Keywords

-

Categories

Oncology Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

Maite Alvarez, Carmen Molina, Saray Garasa, Maria C. Ochoa, Maria E. Rodriguez-Ruiz, Gabriel Gomis, Assunta Cirella, Irene Olivera, Javier Glez-Vaz, Jose Gonzalez-Gomariz, Carlos luri-Rey, Arantza Azpilikueta, Elixabet Bolanos, Alvaro Teijeira, Pedro Berraondo, Marisol Quintero, Ignacio Melero

Summary: The poly I:C-based viral mimetic BO-112 has been found to effectively reduce tumor metastasis when intratumorally delivered, particularly when combined with systemic anti-PD-1 mAbs. This neoadjuvant immunotherapy approach relies on antigen-specific effector CD8 T cells and cDC1 antigen-presenting cells.

ONCOIMMUNOLOGY (2023)

Add to Collection

Article Oncology

Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

Maria E. Rodriguez-Ruiz, Irantzu Serrano-Mendioroz, Eneko Garate-Soraluze, Paloma Sanchez-Mateos, Celia Barrio-Alonso, Inmaculada Rodriguez Lopez, Victor Diaz Pascual, Leire Arbea Moreno, Maite Alvarez, Miguel F. Sanmamed, Jose Luis Perez-Gracia, Helena Escuin-Ordinas, Marisol Quintero, Ignacio Melero

Summary: This study demonstrates that local BO-112 immunotherapy and focal irradiation can synergistically achieve local tumor control. Furthermore, irradiation plus BO-112 in one of the tumor lesions enhances the therapeutic effects on distant irradiated lesions that were not injected with BO-112.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew S. Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily Higgs, Riyue Bao, Timothy C. Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil Khushalani, Jason J. Luke

Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

Maite Alvarez, Carmen Molina, Carlos E. De Andrea, Myriam Fernandez-Sendin, Maria Villalba, Jose Gonzalez-Gomariz, Maria Carmen Ochoa, Alvaro Teijeira, Javier Glez-Vaz, Fernando Aranda, Miguel F. Sanmamed, Maria E. Rodriguez-Ruiz, Xinyi Fan, Wen H. Shen, Pedro Berraondo, Marisol Quintero, Ignacio Melero

Summary: Clinically feasible co-injections of BO-112 and a STING agonist achieve synergistic efficacy in eradicating distant untreated tumor lesions. This synergistic effect is dependent on CD8 T cell lymphocytes, conventional type 1 dendritic cells, responsiveness to type I interferon (IFN), and STING function in the tumor-bearing host. Efficacy can be further enhanced with concurrent PD-1 blockade.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Clinical Neurology

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy

Nora Mohn, Mike P. Wattjes, Ortwin Adams, Sandra Nay, Daria Tkachenko, Friederike Salge, Johanne Heine, Kaweh Pars, Gunter Hoglinger, Gesine Respondek, Martin Stangel, Thomas Skripuletz, Roland Jacobs, Kurt-Wolfram Suhs

Summary: Reactivation of human JC polyoma virus (JCPyV) leads to progressive multifocal leukoencephalopathy (PML) caused mainly by immunosuppression, resulting in various neurological deficits. Currently, there is no effective therapy for PML.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Article Oncology

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma

Eiji Kiyohara, Atsushi Tanemura, Kazuma Sakura, Toshihiro Nakajima, Akira Myoui, Naoya Yamazaki, Yoshio Kiyohara, Ichiro Katayama, Manabu Fujimoto, Yasufumi Kaneda

Summary: This study conducted a phase Ia clinical trial of intratumoral administration of GEN0101 in six patients with malignant melanoma. The results showed that GEN0101 had good safety and tolerability, and significant antitumor effects, suggesting its potential as a promising new drug for advanced melanoma patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study

Ann W. Silk, Steven J. O'Day, Howard L. Kaufman, Jennifer Bryan, Jacqueline T. Norrell, Casey Imbergamo, Daniella Portal, Edwin Zambrano-Acosta, Marisa Palmeri, Seymour Fein, Cai Wu, Leslie Guerreiro, Daniel Medina, Praveen K. Bommareddy, Andrew Zloza, Bernard A. Fox, Carmen Ballesteros-Merino, Yixin Ren, Darren Shafren, Mark Grose, Joshua A. Vieth, Janice M. Mehnert

Summary: The CAPRA study suggests that the combination of Coxsackievirus A21 (V937) + pembrolizumab may induce responses in patients with melanoma without a typical immune-active microenvironment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Add to Collection

Article Oncology

A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma

Daniel J. Olson, Jason J. Luke

Summary: This article discusses the results of a clinical study on the use of combination therapy with pembrolizumab and ipilimumab for advanced melanoma treatment. The study showed that the combination treatment was more effective than ipilimumab alone, with many patients experiencing long-term remission and similar rates of side effects.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma

Alexander N. Shoushtari, Anthony J. Olszanski, Marta Nyakas, Thomas J. Hornyak, Jedd D. Wolchok, Victor Levitsky, Lukasz Kuryk, Thomas B. Hansen, Magnus Jaderberg

Summary: This study investigated the efficacy of ONCOS-102 (an oncolytic adenovirus expressing GM-CSF) combined with anti-PD-1 therapy in patients with anti-PD-1-resistant melanoma. The results showed that the combination treatment was well tolerated and resulted in clinical benefit by promoting T-cell infiltration, particularly cytotoxic CD8+ T cells, in the tumor microenvironment.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Hansol Lee, Angela L. Ferguson, Camelia Quek, Ismael A. Vergara, Ines Pires daSilva, Ruth Allen, Tuba Nur Gide, Jordan W. Conway, Lambros T. Koufariotis, Nicholas K. Hayward, Nicola Waddell, Matteo S. Carlino, Alexander M. Menzies, Robyn P. M. Saw, Elena Shklovskaya, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long, Umaimaintha Palendira, James S. Wilmott

Summary: This study characterized intratumoral macrophage populations in melanoma biopsies and investigated the association between CD16-expressing macrophage densities and treatment outcomes for patients receiving anti-PD-1 monotherapy or a combination with anti-CTLA-4. The results showed that patients who responded to combination therapy had higher CD16 macrophage densities compared to those who did not respond. Additionally, patients with high intratumoral densities of CD16 macrophages had a significantly longer progression-free survival. These findings suggest that CD16 macrophages may serve as a potential biomarker for response to combination immunotherapies in metastatic melanoma patients.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Shipra Gandhi, Manu R. Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen, Cheryl Allen, Joseph D. Tario, Paul K. Wallace, Carlos D. Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J. Drabick, Mark J. Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A. Repasky, Marc S. Ernstoff

Summary: The combination of propranolol with pembrolizumab in treatment-naive metastatic melanoma patients is safe and shows very promising activity, with an objective response rate of 78%. While no significant changes in treatment-associated biomarkers were observed in the patients, an increase in IFN gamma and a decrease in IL6 were noted in responders.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Dermatology

Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma

Aarthy K. Uthayakumar, Emily Rudd, Mariana Noy, Justin Weir, James Larkin, Louise Fearfield

Summary: Lichenoid reactions can be a potential severe adverse effect of immune checkpoint inhibitors, with long-term impact on patient's quality of life.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma

Yifeng Xia, Jingjing Wei, Songsong Zhao, Beibei Guo, Fenghua Meng, Bert Klumperman, Zhiyuan Zhong

Summary: The study introduced a robust systemic delivery vehicle, cRGD-CPs, for oncolytic peptide LTX-315, demonstrating significant anti-tumor effects in a mouse model of malignant B16F10 melanoma. The combination with CpG adjuvant and anti-PD-1 antibody enhanced the immunotherapeutic efficacy, leading to tumor regression and long-term immune memory protection in some cases.

JOURNAL OF CONTROLLED RELEASE (2021)

Add to Collection

Article Oncology

Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Ines Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns

Summary: IT co-injection of T-VEC with autologous CD1c (BDCA-1)(+)/CD141 (BDCA-3)(+) myDCs in advanced melanoma patients shows promising early signs of antitumor activity and can lead to durable complete responses in some patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy

R. Kim, M. Kwon, M. An, S. T. Kim, S. A. Smith, A. B. Loembe, P. G. S. Mortimer, J. Armenia, N. Lukashchuk, N. Shah, E. Dean, W. -Y. Park, J. Lee

Summary: Ceralasertib in combination with durvalumab has promising antitumor activity among patients with metastatic melanoma who have failed anti-programmed cell death protein 1 therapy, and shows stable and sustained disease control rate.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Dermatology

Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

Clementine Carlet, Stephane Dalle, Marie-Therese Leccia, Laurent Mortier, Sophie Dalac-Rat, Caroline Dutriaux, Delphine Legoupil, Henri Montaudie, Olivier Dereure, Julie De Quatrebarbes, Florence Granel-Brocard, Myrtille Le-Bouar, Julie Charles, Florence Brunet-Possenti, Brigitte Dreno, Wendy Lefevre, Clara Allayous, Celeste Lebbe, Charlee Nardin

Summary: This study investigated the late-onset adverse events (AEs) in melanoma patients treated with anti-PD1 therapy for at least 2 years. Late-onset AEs were found to be frequent and mostly mild or moderate. Early-onset AEs and prolonged treatment with anti-PD1 therapy were associated with an increased risk of late-onset AEs.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop

Werner Kempf, Tony Petrella, Rein Willemze, Patty Jansen, Emilio Berti, Marco Santucci, Eva Geissinger, Lorenzo Cerroni, Eve Maubec, Maxime Battistella, John Goodlad, Emmanuella Guenova, Katariina Lappalainen, Annamari Ranki, Paul Craig, Eduardo Calonje, Blanca Martin, Sean Whittaker, Ilske Oschlies, Ulrike Wehkamp, Jan P. Nicolay, Marion Wobser, Julia Scarisbruck, Nicola Pimpinelli, Rudi Stadler, Katrin Kerl French, Pietro Quaglino, Jinran Lin, Lianjun Chen, Michaela Beer, Patrick Emanuel, Stephane Dalle, Alistair Robson

Summary: The study retrospectively analyzed a series of 46 patients and biopsies by the international EORTC Cutaneous Lymphoma Group. The dermal CD8(+) lymphoproliferations were categorized into three groups: cutaneous acral CD8(+) T-cell lymphoma, primary cutaneous CD8(+) peripheral T-cell lymphoma, unspecified/NOS, and cutaneous CD8(+) lymphoproliferations associated with congenital immunodeficiency syndromes.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Oncology

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, Stephane Dalle, Marie Maerevoet, Jean-Marie Michot, Vincent Ribrag, Fritz Offner, Marie Beylot-Barry, Helene Moins-Teisserenc, Karen Zwaenepoel, Koen de Winne, Maxime Battistella, Anna Hultberg, Domenica Gandini, Mahan Moshir, Julie Jacobs, Tim Delahaye, Aitzaz Khan, Piotr Zabrocki, Karen Silence, Luc van Rompaey, Christophe Borg, Giovanna Motta, Federica Melle, Angelica Calleri, Patrick Pauwels, Hans de Haard, Stefano Pileri, Martine Bagot

Summary: The study investigated the clinical benefit of cusatuzumab in patients with relapsed/refractory cutaneous T-cell lymphoma. Results showed an overall response rate of 23%, with a better response in patients with Sezary syndrome at a dosage of 5mg/kg.

CANCER (2022)

Add to Collection

Letter Dermatology

Atypical extensive lupus tumidus-like eruption as an early presentation of VEXAS syndrome

Emmanuel Ribereau-Gayon, Mael Heiblig, Estelle Bourbon, Pierre Sujobert, Olivier Harou, Claire Theillac, Nicolas Poulalhon, Brigitte Balme, Stephane Dalle, Sebastien Debarbieux

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Adipocyte Extracellular Vesicles Decrease p16INK4A in Melanoma: An Additional Link between Obesity and Cancer

Ikrame Lazar, Emily Clement, Lorry Carrie, David Esteve, Stephanie Dauvillier, Mohamed Moutahir, Stephane Dalle, Veronique Delmas, Nathalie Andrieu-Abadie, Lionel Larue, Catherine Muller, Laurence Nieto

Summary: Obesity is associated with the occurrence and development of melanoma. The mechanism involves the downregulation of p16(INK4A) expression in melanoma cells by adipocytes through beta-catenin-dependent regulation, which increases cell motility. Adipocytes from individuals with obesity secrete a larger number of vesicles, delivering more beta-catenin to melanoma cells.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society

Felix Pham, Amelie Boespflug, Gerard Duru, Alice Phan, Nicolas Poulalhon, Laura Weiler, Masaru Tanaka, Aimilios Lallas, Dai Ogata, Anne Celine Davaine, Philippe Bahadoran, Xavier Balguerie, Grazyna Kaminska-Winciorek, Isabelle Tromme, Osvaldo Correia, Moon-Bum Kim, Ashfaq A. Marghoob, Linda Martin, Pascale Guitera, Mariame Meziane, Juliette Miquel, Je-Ho Mun, Giuseppe Argenziano, Didier Bessis, Johnny Bourke, Zeljko Mijuskovic, Christine Chiaverini, Cloe Corven-Benoit, Catherine Droitcourt, Francois Skowron, Myriam Marque, Iris Zalaudek, Cliff Rosendahl, David Moreno-Ramirez, Pierre Vabres, Holger Haenssle, Josep Malvehy, Susana Puig, Caroline Robert, Thomas R. Schopf, Alon Scope, Stephane Dalle, Luc Thomas

Summary: Congenital nail matrix nevi (NMN) have clinical and dermatoscopic features similar to adult subungual melanoma. The distal fibrillar (brush-like) pattern is a suggestive feature of congenital and congenital-type NMN.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Article Oncology

ZEB1 transcription factor promotes immune escape in melanoma

Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, Brigitte Balme, Garance Tondeur, Arnaud de la Fouchardiere, Lionel Larue, Alain Puisieux, Yenkel Grinberg-Bleyer, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Stephane Dalle, Julie Caramel

Summary: This study reveals that ZEB1 expression in melanoma cells is associated with decreased CD8(+) T cell infiltration, leading to tumor immune evasion and resistance to immune checkpoint blockade. ZEB1 directly represses the secretion of T cell-attracting chemokines, such as CXCL10, and targeting ZEB1 may enhance the efficacy of immunotherapy in melanoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Rheumatology

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study

Leo Placais, Stephane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudie, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, Francois Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Celeste Lebbe

Summary: This study found that patients with pre-existing autoimmune disease (pAID) who received immune checkpoint inhibitors (ICIs) for melanoma treatment were at higher risk of immune-related adverse events (irAEs). However, they had a better 24-month survival rate compared to the control group.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Dermatology

Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study

Luojun Wang, Delphine Rocas, Stephane Dalle, Nouhoum Sako, Laura Pelletier, Nadine Martin, Aurelie Dupuy, Nadia Tazi, Brigitte Balme, Beatrice Vergier, Marie Beylot-Barry, Agnes Carlotti, Martine Bagot, Maxime Battistella, Guillaume Chaby, Saskia Ingen-Housz-Oro, Philippe Gaulard, Nicolas Ortonne

Summary: Patients with pcTFH-PTCL have clinicopathological and molecular characteristics that overlap with systemic lymphoma of TFH derivation. Most patients remain confined to the skin, with only a small number developing systemic disease and death.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

Martine Bagot, Stephane Dalle, Lubomir Sokol, Athansios Tsianakas, Amy Musiek, Pablo L. Ortiz-Romero, Brian Poligone, Madeleine Duvic, Craig Elmets, Mollie Leoni, Karen Dwyer, Takahiro Ito, Fiona Herr, Youn H. Kim

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Ocular Inflammation Induced by Immune Checkpoint Inhibitors

Florence Chaudot, Pascal Seve, Antoine Rousseau, Alexandre Thibault Jacques Maria, Pierre Fournie, Pierre Lozach, Jeremy Keraen, Marion Servant, Romain Muller, Baptiste Gramont, Sara Touhami, Habeeb Mahmoud, Pierre-Antoine Quintart, Stephane Dalle, Olivier Lambotte, Laurent Kodjikian, Yvan Jamilloux

Summary: This study analyzed ocular immunotherapy-related adverse events (IRAEs) diagnosed in France after the marketing of immune checkpoint inhibitors (ICPIs). The results showed that these events were more common in patients undergoing treatment for metastatic melanoma, and local or systemic corticosteroids were effective in controlling them.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab

Felix Pham, Samy Belkaid, Denis Maillet, Cyrille B. Confavreux, Stephane Dalle, Julien Peron

Summary: The presence of baseline bone metastases appears to be associated with worse outcomes in RCC combo-ICI-treated patients, while its effect may not be independent from the inflammatory state. However, bone metastases seem to have no impact on the outcomes of melanoma combo-ICI-treated patients.

BIOMEDICINES (2022)

Add to Collection

Article Dermatology

Clinical Features, Histological Characteristics, and Disease Outcomes of Mycosis Fungoides in Children and Adolescents: A Nationwide Multicentre Cohort of 46 Patients

Anne Welfringer-Morin, Marion Barroil, Sylvie Fraitag, Vanessa Szablewski, Olivia Boccara, Jean-Philippe Lacoure, Christine Christine, Martine Bagot, Caroline Ram-Wolff, Marie-Dominique Vignon-Pennamen, Stephane Dalle, Michel D'incan, Florent Amatore, Marie Beylot-Barry, Beatric Vergier, Juliette Mazereeuw-Hautier, Billal Tedbirt, Gaelle Quereux, Olivier Carpentier, Francois Skowron, Yves Bertrand, Pascal Van Eeckhout, Valerie Dekeuleneer, Charlee Nardinu, Henri Adamski, Saskia Ingen-Housz-Oro, Olivier Dereure, Christine Bodemer

Summary: This study retrospectively analyzed the clinical, histological characteristics, and disease outcome of childhood mycosis fungoides (MF) patients. The results showed that most patients were in stage I MF with a high frequency of hypopigmented and folliculotropic lesions, and a significant presence of CD8+ immunophenotype. Treatment options included wait-and-see, skin-directed, and systemic treatments, with a good clinical response observed in the majority of patients, although some experienced relapse after initial response. The long-term prognosis was generally indolent, but a small portion of patients may have persistent MF into adulthood.

DERMATOLOGY (2023)

Add to Collection

Letter Dermatology

Use of Reflectance Confocal Microscopy in Equivocal Lesions for the Diagnosis of Melanoma

Felix Pham, Stephane Dalle

JAMA DERMATOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy

Caleigh Mandel-Brehm, Sara E. Vazquez, Christopher Liverman, Mickie Cheng, Zoe Quandt, Andrew F. Kung, Audrey Parent, Brenda Miao, Emmanuel Disse, Christine Cugnet-Anceau, Stephane Dalle, Elizaveta Orlova, Elena Frolova, Diana Alba, Aaron Michels, Bergithe E. Oftedal, Michail S. Lionakis, Eystein S. Husebye, Anil K. Agarwal, Xilong Li, Chengsong Zhu, Quan Li, Elif Oral, Rebecca Brown, Mark S. Anderson, Abhinmanyu Garg, Joseph L. DeRisi

Summary: This study identified autoantibodies to PLIN1 in a murine model of APS1 and in patients with acquired lipodystrophy, indicating that PLIN1 autoantibodies may be markers of acquired autoimmune lipodystrophies.

DIABETES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.